drugset / Trial / NCT05397379
A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of HEC96719 in non-cirrhotic NASH patients.
Timeline
- Start
- 2021-11-15
- Primary completion
- 2023-09-05
- Completion
- 2023-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEC96719 | Unknown | 0.25 mg | Oral |
| Subject | HEC96719 | Unknown | 0.35 mg | Oral |
| Subject | HEC96719 | Unknown | 0.5 mg | Oral |